Frailty check could predict chemo danger for seniors
NCT ID NCT07624370
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how frailty—a state of weakness and reduced physical function—affects the risk of severe side effects from chemotherapy in people aged 70 and older with cancer. Researchers will assess 160 patients using various tests for frailty, muscle loss, and overall health before treatment. The goal is to see if frailty can predict who will experience serious toxicity, helping doctors tailor treatments more safely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors identify which older patients are at higher risk of severe side effects from chemotherapy, leading to more personalized and safer treatment plans.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly improve outcomes. Results may not apply to all cancer types or treatment settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Trial Office-ASST Ovest Milanese
Legnano, Italy, 20025, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a simple CT scan catch lung cancer earlier in kuwait?
- A stitch in time: could a device make abdominal closure safer?
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?